Vericel Corporation (VCEL)

NASDAQ: VCEL · IEX Real-Time Price · USD
52.18
-0.15 (-0.29%)
Mar 28, 2024, 1:10 PM EDT - Market open

Company Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.

The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vericel Corporation
Vericel logo
Country United States
Founded 1989
IPO Date Feb 4, 1997
Industry Biotechnology
Sector Healthcare
Employees 314
CEO Dominick C. Colangelo Esq.

Contact Details

Address:
64 Sidney St.
Cambridge, Massachusetts 02139
United States
Phone (734) 930-5555
Website vcel.com

Stock Details

Ticker Symbol VCEL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000887359
CUSIP Number 92346J108
ISIN Number US92346J1088
Employer ID 94-3096597
SIC Code 2836

Key Executives

Name Position
Dominick C. Colangelo Esq. Chief Executive Officer, President and Director
Joseph Anthony Mara Jr. Chief Financial Officer and Treasurer
Michael Halpin Chief Operating Officer
Sean C. Flynn Senior Vice President, General Counsel and Secretary
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. Chief Medical Officer
Jonathan D. Siegal Principal Accounting Officer, Vice President and Corporate Controller
Eric Burns Vice President of Finance and Investor Relations
Patrick J. Fowler Senior Vice President of Corporate Development and Strategy
Patrick Helfrich Vice President of Marketing and Commercial Strategy
Heidi Hassen Senior Vice President of Human Resources

Latest SEC Filings

Date Type Title
Mar 27, 2024 144 Filing
Mar 21, 2024 ARS Filing
Mar 21, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 21, 2024 DEF 14A Other definitive proxy statements
Mar 14, 2024 144 Filing
Mar 13, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 8, 2024 144 Filing
Mar 7, 2024 144 Filing
Feb 29, 2024 10-K Annual Report